H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $518 from $478 and keeps a Buy rating on the shares. The firm cites continued momentum across the company’s cystic fibrosis, Casgevy, and Journavax portfolios for the target boost.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals reports Q4 adjusted EPS $5.03, consensus $5.15
- Vertex Pharmaceuticals sees FY26 revenue $12.95B-$13.1B, consensus $13B
- Notable companies reporting after market close
- These Are the Stocks Reporting Earnings Today – February 12, 2026
- Vertex Pharmaceuticals’ povetacicept granted FDA orphan designation